× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.


meta|Evidence - COVID-19

Living meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En     Fr

Our approach


adjuvant therapies

anticoagulant 1

anticoagulant, curative dose 1

anticoagulant, pre-admission 3

anticoagulant, prophylactic dose 2

sulodexide

face mask

anti-inflammatoty and immuno-therapy

anti-inflammatory therapies

colchicine 1

non-steroidal anti-inflammatory drugs 4

Ibuprofen 1

corticosteroids 1

Immunostimulants drugs

convalescent plasma treatment

interferon

IFN beta-1a

levamisole

neutralizing antibody

casirivimab/imdevimab (Ronapreve) 1

Immunosuppressants drugs

anti-interleukin-6

tocilizumab 1

statins

antiandrogenic

5-alpha-reductase inhibitors

antiviral and associated therapy

azithromycin

bromhexine

chloroquine and derivatives

chloroquine

hydroxychloroquine

doxycycline

favipiravir

fluvoxamine

hydroxychloroquine plus macrolides

ivermectin 1

lopinavir/ritonavir

zinc 1

Drugs for acid related disorders

proton pump inhibitors (PPI) 3

miscellaneous

2-deoxy-D-glucose (2-DG)

acetylcysteine

calcium channel blocker

kinin-kallikrein inhibitors

nicotin

ozonated autohemotherapy

radiotherapy

Oral antidiabetic drugs

DPP-4 inhibitor

metformin

Renin-angiotensin-system-acting agents 1

angiotensin converting enzyme inhibitors (ACEIs)

angiotensin receptor blockers (ARBs)

vaccines

BCG vaccination

DNA vaccine

bacTRL-Spike

Vitamins

vitamin C

Follow-us

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons